Skip to main content
. Author manuscript; available in PMC: 2013 Mar 5.
Published in final edited form as: Mol Pharm. 2012 Feb 13;9(3):634–644. doi: 10.1021/mp200571k

Table 1.

Comparison of IC50 Values for Mitaplatin, Cisplatin, and DCA to CP-s and CP-r Cells as Determined by the MTT Assaya

IC50 (µM)
KB-3-1 KB-CP 20 BEL 7404 BEL 7404-CP 20
mitaplatin 3.47 ± 0.13   50.35 ± 4.95 *** 6.84 ± 0.81   41.71 ± 2.30 ***
cisplatin 5.68 ± 1.22 123.78 ± 1.86 7.20 ± 0.74 169.56 ± 4.56
cisplatin + 2DCA 6.89 ± 0.13 117.43 ± 0.85 7.13 ± 1.25 160.89 ± 0.11
2DCA >60 >600 >200 >600
a

Data were the mean ± SD from three independent experiments.

***

P < 0.001 versus cisplatin treatment group.